Pyrimidine substituted macrocyclic HCV inhibitors

US8937080B2 · kind B2 · utility

Assignees

• MEDIVIR AB · SE
• Janssen R & D Ireland · IE

Inventors

• Pierre Jean-Marie Bernard Raboisson · Sligo, IE
• Anna Karin Gertrud Linnea Belfrage · Huddinge, SE
• Bjorn Classon · Stockholm, SE
• Karin Charlotta Lindquist · Huddinge, SE
• Karl Magnus Nilsson · Vimmerby, SE
• Asa Annica Kristina Rosenquist · Huddinge, SE
• Bertil Samuelsson · Huddinge, SE
• Horst Wahling · Huddinge, SE

Key dates

• Filing date: Feb 8, 2008
• Grant date: Jan 20, 2015
• Expiry date: May 12, 2029

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula I:including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.